Clinical trials: Neoantigen
Cancer of Gastrointestinal Tract
Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
The purpose of this study is to determine if it is possible to make and safely administer a 'personalized' cancer vaccine for people diagnosed with an upper gastrointestinal tract cancer.
- Trial name
- NCT05153304
- Testing
- personalized vaccine, Nivolumab
- Where
- United States
- Sponsor
- University of California, San Diego
Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms
A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal squamous carcinoma, gastric…
- Conditions
- Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Colorectal Adenocarcinoma
- Trial name
- NCT03468244
- Testing
- Personalized mRNA Tumor Vaccine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Changhai Hospital
Glioblastoma
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
This research study is studying a new type of vaccine as a possible treatment for patients with glioblastoma. This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also…
- Trial name
- NCT02287428
- Testing
- Radiation Therapy, Personalized NeoAntigen Peptides, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Dana-Farber Cancer Institute
Pancreatic Cancer
Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
This is a phase 1, open-label study to evaluate the safety and tolerability of neoantigen personalized mRNA tumour vaccine combined with Adebrelimab (a PD-L1 humanized monoclonal antibody) in patients with surgically resected…
- Trial name
- NCT06156267
- Testing
- Adebrelimab, mRNA tumor vaccines
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
This study is a single-arm phase I/II clinical study to evaluate the effectiveness of evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy (iNeo-Vac-R01) in combination with PD-1 antibody and standard…
- Trial name
- NCT06888648
- Testing
- individualized anti-tumor new antigen iNeo-Vac-R01 injection, mFOLFIRINOX Treatment Regimen, Sintilimab injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Metastatic Colorectal Cancer, Stage II/III Colon Cancer
A Screening Study Targeting Tumor-specific Antigens
The purpose of this study is to identify patients who may be eligible to participate in a separate Phase 2/3 treatment study evaluating an individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of…
- Trial name
- NCT05158621
- Testing
- blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA])
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gritstone bio, Inc.
Gastric Cancer
Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer
This trial is an investigator-initiated, single-center, open-label, single-arm exploratory study of mRNA neoantigen tumor vaccine in the treatment of advanced gastric cancer, including two phases: dose escalation and dose…
- Trial name
- NCT05227378
- Testing
- neoantigen tumor vaccine with or without PD-1/L1
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shen Lin
Unmethylated Glioblastoma
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
This is a single institution, open-label, multi-arm, phase I study assessing the safety and immunogenicity of a personalized neoantigen-based personalized DNA vaccine combined with PD-1 blockade therapy in subjects with newly…
- Trial name
- NCT05743595
- Testing
- Personalized Neoantigen DNA vaccine, Retifanlimab, TDS-IM v 2.0 electroporation device
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Advanced Solid Tumor
Neoantigen-expanded Autologous Immune Cell Therapy
The investigators aim to investigate the patient's tumor neoantigen to generate "personalized cancer vaccine" and then to expand autologous dendritic cells-cytokine-induced killer cells (DC-CIK).
- Trial name
- NCT05020119
- Testing
- Neoantigen-expanded cell therapy.
- Where
- Taiwan
- Volunteers
- 9 people
- Sponsor
- Chang Gung Memorial Hospital
Refractory Tumor, Solid Tumor
Neoantigen Derived DCs as Cancer Treatment
Tumor lysate or carcinoembryonic antigen (CEA) derived DCs-based therapy is safe and can elicites remarkable T-cell responses but mostly did not really transfer into significant clinical benefit.
- Trial name
- NCT05767684
- Testing
- Dendritic Cell Vaccine, Lenvatinib, Nivolumab
- Where
- 3 sites in Taiwan
- Volunteers
- 12 people
- Sponsor
- National Health Research Institutes, Taiwan
Colorectal Cancer, Pancreatic Cancer
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as patients with metastatic colorectal cancer who have exposure to 2 or more lines of chemotherapy, to…
- Trial name
- NCT04117087
- Testing
- KRAS peptide vaccine, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer, Solid Tumor
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
- Trial name
- NCT05741242
- Testing
- Personalized Synthetic Long Peptide Vaccine
- Where
- 6 sites in United States
- Volunteers
- 136 people
- Sponsor
- Jaime Leandro Foundation for Therapeutic Cancer Vaccines
Advanced Hepatocellular Carcinoma (HCC)
Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
This study is to evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy iNeo-Vac-R01 combined with PD-1 monoclonal antibody, anti-VEGFR monoclonal antibody and TACE regimen for the treatment of patients…
- Trial name
- NCT06995105
- Testing
- TACE, Sintilimab combined with Bevacizumab, individualized anti-tumor new antigen iNeo-Vac-R01 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Urothelial/Bladder Cancer, Nos
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer
The purpose of this study is to determine the good and bad effects of atezolizumab given in combination with a personalized cancer vaccine in patients with urothelial cancer either after surgery to remove organ where the tumor…
- Trial name
- NCT03359239
- Testing
- Atezolizumab, PGV001, Poly ICLC
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Matthew Galsky
Solid Tumor, Adult
Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors
The WES and RAN-seq will be performed to identify and verify neoantigens and appropriate mRNA sequences will be verified, manufactured and protected for vaccine production by multiple in vitro and in vivo studies.
- Trial name
- NCT06195384
- Testing
- Neoantigen mRNA Vaccine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Lung Cancer
DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs
This is a single-center, single-arm, prospective clinical trial to investigate the safety and efficacy of Neo-DCVac combined with ICIs in the treatment of advanced lung cancer resistant to ICIs.
- Trial name
- NCT06329908
- Testing
- LG002
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhen-Yu Ding
Hepatocellular Carcinoma
Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma
In this study, safety and effects of IPM001 vaccine on human hepatocellular carcinoma are going to be investigated, IPM001 is a neoantigen/tumor-specific antigen sensitized autoimmune cell injection
- Trial name
- NCT05105815
- Testing
- IPM001
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Huashan Hospital
Advanced NSCLC
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
In this study, the investigators provide a combined treatment of personalized tumor neoantigen-loaded dendritic cell (DC) vaccine, PD-1 Inhibitor, and radiotherapy to patients with advanced non-small cell lung cancer (NSCLC)…
- Trial name
- NCT06751849
- Testing
- Radiotherapy, PD-1 inhibitor, Neoantigen-loaded DC vaccine
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Melanoma
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
This research study is evaluating a new type of melanoma vaccine called "Personalized NeoAntigen Cancer Vaccine". The purpose of this study is to determine if it is possible to make and administer safely a vaccine against…
- Trial name
- NCT01970358
- Testing
- Poly-ICLC, Peptides
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Patrick Ott, MD, PhD
Non Small Cell Lung Cancer, Colorectal Cancer
A Study of a Personalized Neoantigen Cancer Vaccine
The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination with nivolumab and ipilimumab, in patients…
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT03639714
- Testing
- GRT-C901, GRT-R902, nivolumab
- Where
- 11 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Gritstone bio, Inc.